nach oben

Erschienen in:

08.01.2019 | Diagnostic Neuroradiology

MRI features suggestive of gadolinium retention do not correlate with Expanded Disability Status Scale worsening in Multiple Sclerosis

verfasst von: Sirio Cocozza, Giuseppe Pontillo, Roberta Lanzillo, Camilla Russo, Maria Petracca, Martina Di Stasi, Chiara Paolella, Elena Augusta Vola, Chiara Criscuolo, Marcello Moccia, Anna Lamberti, Serena Monti, Vincenzo Brescia Morra, Andrea Elefante, Giuseppe Palma, Enrico Tedeschi, Arturo Brunetti

Erschienen in: Neuroradiology | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Different studies showed correlations between gadolinium-based contrast agent (GBCA) administrations and dentate nucleus (DN) T1-weighted hyperintensity. The clinical impact of gadolinium retention, however, is still largely unknown. The aim of this study was to investigate relations between MRI and clinical disability in relapsing–remitting multiple sclerosis (RR-MS) patients.

Methods

In this retrospective study, clinical data were obtained from 74 RR-MS patients at baseline and after a mean follow-up time of 3.6 years, including the expanded disability status scale (EDSS) score and its change (ΔEDSS). Patients were considered showing clinical worsening if they score a ΔEDSS ≥ 1 (for baseline EDSS ≤ 5.5) or ΔEDSS ≥ 0.5 (for baseline EDSS > 5.5). From the MRI data, the presence of bilateral DN hyperintensity was recorded along with the calculation of longitudinal relaxation rate (R1) maps.

Results

Patients with DN hyperintensity showed similar ΔEDSS change compared to those without visible changes on T1-weighted images (p = 0.32). Similarly, no DN-R1 difference was found comparing stable patients with those showing a significant clinical worsening (p = 0.54). Finally, no significant effect of DN-R1 values explained the variance in ΔEDSS (p = 0.76), thus suggesting their independence from the clinical outcome.

Conclusions

MS patients with DN hyperintensity show similar EDSS changes compared to subjects without DN high-signal intensity. Furthermore, mean DN-R1 values of patients with significant clinical worsening were comparable to those of stable subjects and were unrelated to clinical disability. Taken together, these findings suggest that gadolinium retention in the brain of MS patients does not affect their clinical worsening, expressed by the EDSS change.

Aime S, Caravan P (2009) Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging 30(6):1259–1267. https://doi.org/10.1002/jmri.21969 CrossRefPubMedPubMedCentral

Kanal E, Maravilla K, Rowley HA (2014) Gadolinium contrast agents for CNS imaging: current concepts and clinical evidence. AJNR Am J Neuroradiol 35(12):2215–2226. https://doi.org/10.3174/ajnr.A3917 CrossRefPubMedPubMedCentral

Jung JW, Kang HR, Kim MH, Lee W, Min KU, Han MH, Cho SH (2012) Immediate hypersensitivity reaction to gadolinium-based MR contrast media. Radiology 264(2):414–422. https://doi.org/10.1148/radiol.12112025 CrossRefPubMed

Grobner T (2006) Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21(4):1104–1108. https://doi.org/10.1093/ndt/gfk062 CrossRefPubMed

McDonald RJ, Levine D, Weinreb J, Kanal E, Davenport MS, Ellis JH, Jacobs PM, Lenkinski RE, Maravilla KR, Prince MR, Rowley HA, Tweedle MF, Kressel HY (2018) Gadolinium retention: a research roadmap from the 2018 NIH/ACR/RSNA workshop on gadolinium chelates. Radiology 181151:517–534. https://doi.org/10.1148/radiol.2018181151 CrossRef

U.S. Food & Drug Administration (2017) 2017 Meeting Materials, Medical Imaging Drugs Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/MedicalImagingDrugsAdvisoryCommittee/ucm553470.htm

Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D (2014) High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 270(3):834–841. https://doi.org/10.1148/radiol.13131669 CrossRefPubMed

Roberts DR, Holden KR (2016) Progressive increase of T1 signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images in the pediatric brain exposed to multiple doses of gadolinium contrast. Brain and Development 38(3):331–336. https://doi.org/10.1016/j.braindev.2015.08.009 CrossRefPubMed

Tedeschi E, Caranci F, Giordano F, Angelini V, Cocozza S, Brunetti A (2017) Gadolinium retention in the body: what we know and what we can do. Radiol Med 122(8):589–600. https://doi.org/10.1007/s11547-017-0757-3 CrossRefPubMed

10.

Gulani V, Calamante F, Shellock FG, Kanal E, Reeder SB (2017) Gadolinium deposition in the brain: summary of evidence and recommendations. Lancet Neurol 16(7):564–570. https://doi.org/10.1016/S1474-4422(17)30158-8 CrossRefPubMed

11.

McDonald RJ, McDonald JS, Kallmes DF, Jentoft ME, Murray DL, Thielen KR, Williamson EE, Eckel LJ (2015) Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 275(3):772–782. https://doi.org/10.1148/radiol.15150025 CrossRefPubMed

12.

Ramalho J, Castillo M, AlObaidy M, Nunes RH, Ramalho M, Dale BM, Semelka RC (2015) High signal intensity in globus pallidus and dentate nucleus on unenhanced T1-weighted MR images: evaluation of two linear gadolinium-based contrast agents. Radiology 276(3):836–844. https://doi.org/10.1148/radiol.2015150872 CrossRefPubMed

13.

Robert P, Fingerhut S, Factor C, Vives V, Letien J, Sperling M, Rasschaert M, Santus R, Ballet S, Idee JM, Corot C, Karst U (2018) One-year retention of gadolinium in the brain: comparison of gadodiamide and gadoterate meglumine in a rodent model. Radiology 172746:424–433. https://doi.org/10.1148/radiol.2018172746 CrossRef

14.

Smith AP, Marino M, Roberts J, Crowder JM, Castle J, Lowery L, Morton C, Hibberd MG, Evans PM (2017) Clearance of gadolinium from the brain with no pathologic effect after repeated administration of gadodiamide in healthy rats: an analytical and histologic study. Radiology 282(3):743–751. https://doi.org/10.1148/radiol.2016160905 CrossRefPubMed

15.

Kanda T, Fukusato T, Matsuda M, Toyoda K, Oba H, Kotoku J, Haruyama T, Kitajima K, Furui S (2015) Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 276(1):228–232. https://doi.org/10.1148/radiol.2015142690 CrossRefPubMed

16.

Murata N, Gonzalez-Cuyar LF, Murata K, Fligner C, Dills R, Hippe D, Maravilla KR (2016) Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: preliminary results from 9 patients with normal renal function. Investig Radiol 51(7):447–453. https://doi.org/10.1097/RLI.0000000000000252 CrossRef

17.

Forslin Y, Shams S, Hashim F, Aspelin P, Bergendal G, Martola J, Fredrikson S, Kristoffersen-Wiberg M, Granberg T (2017) Retention of gadolinium-based contrast agents in multiple sclerosis: retrospective analysis of an 18-year longitudinal study. AJNR Am J Neuroradiol 38(7):1311–1316. https://doi.org/10.3174/ajnr.A5211 CrossRefPubMedPubMedCentral

18.

Burke LM, Ramalho M, AlObaidy M, Chang E, Jay M, Semelka RC (2016) Self-reported gadolinium toxicity: a survey of patients with chronic symptoms. Magn Reson Imaging 34(8):1078–1080. https://doi.org/10.1016/j.mri.2016.05.005 CrossRefPubMed

19.

Semelka RC, Commander CW, Jay M, Burke LM, Ramalho M (2016) Presumed gadolinium toxicity in subjects with normal renal function: a report of 4 cases. Investig Radiol 51(10):661–665. https://doi.org/10.1097/RLI.0000000000000318 CrossRef

20.

Semelka RC, Ramalho J, Vakharia A, AlObaidy M, Burke LM, Jay M, Ramalho M (2016) Gadolinium deposition disease: initial description of a disease that has been around for a while. Magn Reson Imaging 34(10):1383–1390. https://doi.org/10.1016/j.mri.2016.07.016 CrossRefPubMed

21.

Semelka RC, Ramalho M, AlObaidy M, Ramalho J (2016) Gadolinium in humans: a family of disorders. AJR Am J Roentgenol 207(2):229–233. https://doi.org/10.2214/AJR.15.15842 CrossRefPubMed

22.

Tedeschi E, Palma G, Canna A, Cocozza S, Russo C, Borrelli P, Lanzillo R, Angelini V, Postiglione E, Morra VB, Salvatore M, Brunetti A, Quarantelli M (2016) In vivo dentate nucleus MRI relaxometry correlates with previous administration of gadolinium-based contrast agents. Eur Radiol 26(12):4577–4584. https://doi.org/10.1007/s00330-016-4245-2 CrossRefPubMed

23.

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302. https://doi.org/10.1002/ana.22366 CrossRefPubMedPubMedCentral

24.

Meyer-Moock S, Feng YS, Maeurer M, Dippel FW, Kohlmann T (2014) Systematic literature review and validity evaluation of the expanded disability status scale (EDSS) and the multiple sclerosis functional composite (MSFC) in patients with multiple sclerosis. BMC Neurol 14:58. https://doi.org/10.1186/1471-2377-14-58 CrossRefPubMedPubMedCentral

25.

Uitdehaag BMJ (2018) Disability outcome measures in phase III clinical trials in multiple sclerosis. CNS Drugs. https://doi.org/10.1007/s40263-018-0530-8

26.

Weinshenker BG (1996) Epidemiology of multiple sclerosis. Neurol Clin 14(2):291–308CrossRefPubMed

27.

Cohen JA, Khatri B, Barkhof F, Comi G, Hartung HP, Montalban X, Pelletier J, Stites T, Ritter S, von Rosenstiel P, Tomic D, Kappos L (2016) Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry 87(5):468–475. https://doi.org/10.1136/jnnp-2015-310597 CrossRefPubMed

28.

Kalincik T, Cutter G, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Hupperts R, Oreja-Guevara C, Boz C, Pucci E, Bergamaschi R, Lechner-Scott J, Alroughani R, Van Pesch V, Iuliano G, Fernandez-Bolanos R, Ramo C, Terzi M, Slee M, Spitaleri D, Verheul F, Cristiano E, Sanchez-Menoyo JL, Fiol M, Gray O, Cabrera-Gomez JA, Barnett M, Butzkueven H (2015) Defining reliable disability outcomes in multiple sclerosis. Brain 138(Pt 11):3287–3298. https://doi.org/10.1093/brain/awv258 CrossRefPubMed

29.

Battaglini M, Jenkinson M, De Stefano N (2012) Evaluating and reducing the impact of white matter lesions on brain volume measurements. Hum Brain Mapp 33(9):2062–2071. https://doi.org/10.1002/hbm.21344 CrossRefPubMed

30.

Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A, De Stefano N (2002) Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 17(1):479–489CrossRefPubMed

31.

Borrelli P, Palma G, Tedeschi E, Cocozza S, Comerci M, Alfano B, Haacke EM, Salvatore M (2015) Improving signal-to-noise ratio in susceptibility weighted imaging: a novel multicomponent non-local approach. PLoS One 10(6):e0126835. https://doi.org/10.1371/journal.pone.0126835 CrossRefPubMedPubMedCentral

32.

Palma G, Tedeschi E, Borrelli P, Cocozza S, Russo C, Liu S, Ye Y, Comerci M, Alfano B, Salvatore M, Haacke EM, Mancini M (2015) A novel multiparametric approach to 3D quantitative MRI of the brain. PLoS One 10(8):e0134963. https://doi.org/10.1371/journal.pone.0134963PONE-D-15-18675 CrossRefPubMedPubMedCentral

33.

Rogosnitzky M, Branch S (2016) Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms. Biometals 29(3):365–376. https://doi.org/10.1007/s10534-016-9931-7 CrossRefPubMedPubMedCentral

34.

Sherry AD, Caravan P, Lenkinski RE (2009) Primer on gadolinium chemistry. J Magn Reson Imaging 30(6):1240–1248. https://doi.org/10.1002/jmri.21966 CrossRefPubMedPubMedCentral

35.

Heinrich MC, Kuhlmann MK, Kohlbacher S, Scheer M, Grgic A, Heckmann MB, Uder M (2007) Cytotoxicity of iodinated and gadolinium-based contrast agents in renal tubular cells at angiographic concentrations: in vitro study. Radiology 242(2):425–434. https://doi.org/10.1148/radiol.2422060245 CrossRefPubMed

36.

Chen R, Ling D, Zhao L, Wang S, Liu Y, Bai R, Baik S, Zhao Y, Chen C, Hyeon T (2015) Parallel comparative studies on mouse toxicity of oxide nanoparticle- and gadolinium-based T1 MRI contrast agents. ACS Nano 9(12):12425–12435. https://doi.org/10.1021/acsnano.5b05783 CrossRefPubMed

37.

Akgun H, Gonlusen G, Cartwright J Jr, Suki WN, Truong LD (2006) Are gadolinium-based contrast media nephrotoxic? A renal biopsy study. Arch Pathol Lab Med 130(9):1354–1357. https://doi.org/10.1043/1543-2165(2006)130[1354:AGCMNA]2.0.CO;2

38.

Hui FK, Mullins M (2009) Persistence of gadolinium contrast enhancement in CSF: a possible harbinger of gadolinium neurotoxicity? AJNR Am J Neuroradiol 30(1):E1. https://doi.org/10.3174/ajnr.A1205 CrossRefPubMedPubMedCentral

39.

Blasco-Perrin H, Glaser B, Pienkowski M, Peron JM, Payen JL (2013) Gadolinium induced recurrent acute pancreatitis. Pancreatology 13(1):88–89CrossRefPubMed

40.

Monti S, Borrelli P, Tedeschi E, Cocozza S, Palma G (2017) RESUME: turning an SWI acquisition into a fast qMRI protocol. PLoS One 12(12):e0189933. https://doi.org/10.1371/journal.pone.0189933 CrossRefPubMedPubMedCentral

41.

Dimitrova A, de Greiff A, Schoch B, Gerwig M, Frings M, Gizewski ER, Timmann D (2006) Activation of cerebellar nuclei comparing finger, foot and tongue movements as revealed by fMRI. Brain Res Bull 71(1–3):233–241. https://doi.org/10.1016/j.brainresbull.2006.09.015 CrossRefPubMed

Titel: MRI features suggestive of gadolinium retention do not correlate with Expanded Disability Status Scale worsening in Multiple Sclerosis
verfasst von: Sirio Cocozza
Giuseppe Pontillo
Roberta Lanzillo
Camilla Russo
Maria Petracca
Martina Di Stasi
Chiara Paolella
Elena Augusta Vola
Chiara Criscuolo
Marcello Moccia
Anna Lamberti
Serena Monti
Vincenzo Brescia Morra
Andrea Elefante
Giuseppe Palma
Enrico Tedeschi
Arturo Brunetti
Publikationsdatum: 08.01.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Neuroradiology / Ausgabe 2/2019
Print ISSN: 0028-3940
Elektronische ISSN: 1432-1920
DOI: https://doi.org/10.1007/s00234-018-02150-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

18.04.2024 | Arterielle Hypertonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

MRI features suggestive of gadolinium retention do not correlate with Expanded Disability Status Scale worsening in Multiple Sclerosis

Abstract

Purpose

Methods

Results

Conclusions

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Update Neurologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Normal development of costal element ossification centers of sacral vertebrae in the fetal spine: a postmortem magnetic resonance imaging study

Comparability of semiautomatic tortuosity measurements in the carotid artery

There is an exception to every rule—T2-FLAIR mismatch sign in gliomas

European Society of Neuroradiology (ESNR)

T1-MPRAGE and T2-FLAIR segmentation of cortical and subcortical brain regions—an MRI evaluation study

Predictive value of neurophysiologic monitoring during neurovascular intervention for postoperative new neurologic deficits

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Update Neurologie